RW COVID-19 Page: Find the latest information on global humanitarian action

Here you can find help on using the website, reading the Terms of Use, and viewing the FAQs and API documentation

Access your account or create a new account for additional features or to post job offers or training opportunities


NEW YORK, Jan. February 2021: UNICEF today announced that it has signed an agreement with Pfizer on behalf of the COVAX facility to supply the Pfizer BioNTech COVID-19 vaccine by 2021

Delivery of the vaccine is expected to begin as early as the first quarter of 2021 once the countries receiving Pfizer BioNTech vaccine doses as part of the COVAX allocation confirm that they fully meet all requirements set by Pfizer / BioNTech and the COVAX system

The aim of the COVAX Facility is to provide the world with the best possible opportunity to make safe, effective COVID-19 vaccines available and affordable to all countries worldwide, regardless of income level. This supply agreement enables UNICEF to sell doses from up to to procure 40 million doses available under the COVAX Facility’s Advance Purchase Agreement (APA) with Pfizer / BioNTech for the full year 2021

The Pfizer-BioNTech COVID-19 vaccine, released on Jan. First to receive the WHO Emergency List (EUL) on December 31, 2020, requires storage in the ultra-cold chain UNICEF has worked with partners around the clock to help governments ensure various COVID-19 vaccines are available in cold chain facilities are stored and distributed with different cold chain requirements

Today’s agreement is the second long-term supply agreement UNICEF has signed on behalf of the COVAX facility with a COVID-19 vaccine manufacturer. Just last week, UNICEF signed an agreement with the Serum Institute of India for access to two vaccines through technology transfer signed by AstraZeneca and Novavax, pending approval of the vaccine by WHO

The COVAX facility, led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO, together with UNICEF, aims to provide at least 2 billion doses of approved COVID-19 vaccines to participating economies to protect health by the end of 2021 and frontline social workers as well as other vulnerable and vulnerable groups

COVAX is the vaccine pillar of the Access to COVID-19 Tool (ACT) Accelerator, a groundbreaking global collaboration to accelerate the development, production and fair access to COVID-19 tests, treatments and vaccines COVAX is owned by Gavi, Coalition for Epidemic Preparedness Innovations (CEPI) and WHO jointly led the aim is to accelerate the development and manufacture of COVID-19 vaccines and to ensure fair and equitable access for every country in the world wwwWerint / Initiatives / Act- Accelerator / Covax UNICEF, working with the PAHO Revolving Fund, is a leader in sourcing and delivering doses of COVID-19 vaccines on behalf of the COVAX facility





Learn more about ReliefWeb, the leading online resource for reliable and timely humanitarian information on global crises and disasters since 1996

OCHA coordinates the global emergency response in order to save lives and protect people in humanitarian crises. We are committed to effective and principled humanitarian action for everyone

COVID-19 vaccine

World news – AU – UNICEF signs supply contract for Pfizer / BioNTech COVID-19 vaccine – World